{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:24:01Z","timestamp":1795094641938,"version":"4.10.2"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":287,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alkermes, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This post hoc analysis examined the efficacy of aripiprazole lauroxil (AL) by baseline severity of illness in the double-blind Aripiprazole Lauroxil and Paliperidone palmitate: INitiation Effectiveness study (NCT03345979) in patients with schizophrenia treated with AL every 2\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Methods<\/jats:title>\n                    <jats:p>Adults with acute schizophrenia were randomized to AL 1064\u00a0mg every 2\u00a0months or active control (paliperidone palmitate [PP] 156\u00a0mg monthly). Based on Clinical Global Impression\u2013Severity scores, baseline severity of illness was categorized as moderate, marked, or severe. Changes from baseline in Positive and Negative Syndrome Scale (PANSS) Total score were assessed at week 25, along with PANSS items related to hostility\/excitement. Numbers of patients with activation adverse events (AEs; anxiety, agitation, and insomnia) were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Of 99 patients assigned to AL, 31 (31%) were moderately ill at baseline, 54 (55%) were markedly ill, and 14 (14%) were severely ill. With AL treatment, mean\u2009\u00b1\u2009SE changes from baseline in PANSS Total score at week 25 were \u221221.1\u2009\u00b1\u20092.5 (moderately ill; baseline, 87.1), \u221224.1\u2009\u00b1\u20091.8 (markedly ill; baseline, 95.3), and \u221225.6\u2009\u00b1\u20096.4 (severely ill, baseline, 106.1). Improvements from baseline in PANSS scores related to hostility\/excitement items were comparable among severity subgroups. No clear pattern of occurrence of the AEs anxiety, agitation, and insomnia was observed across baseline severity groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this post hoc analysis, safety related to activation and efficacy with AL treatment were comparable across baseline severity-of-illness subgroups of patients with schizophrenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgaf023","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:22:40Z","timestamp":1760530960000},"source":"Crossref","is-referenced-by-count":1,"title":["Aripiprazole Lauroxil Every 2\u00a0Months for the Treatment of Adults With Schizophrenia: A Post Hoc Analysis of Efficacy by Baseline Severity of Illness From Phase 3b Clinical Trial Data"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2628-9442","authenticated-orcid":false,"given":"John M","family":"Kane","sequence":"first","affiliation":[{"name":"The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Hempstead, NY 11549 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-023X","authenticated-orcid":false,"given":"James A","family":"McGrory","sequence":"additional","affiliation":[{"name":"Alkermes, Inc. , Waltham, MA 02451-1420 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025111409271132000_ref1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00023210-200216070-00004","article-title":"Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics","volume":"16","author":"Csernansky","year":"2002","journal-title":"CNS Drugs"},{"key":"2025111409271132000_ref2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/ndt.s395383","article-title":"The effect of longer dosing intervals for long-acting injectable antipsychotics on outcomes in schizophrenia","volume":"19","author":"Milz","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025111409271132000_ref3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2025111409271132000_ref4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2025111409271132000_ref5","doi-asserted-by":"publisher","first-page":"19m13207","DOI":"10.4088\/JCP.19m13207","article-title":"Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active control ALPINE study","volume":"81","author":"Weiden","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"2025111409271132000_ref6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2025111409271132000_ref7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"2025111409271132000_ref8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jpsychires.2022.12.044","article-title":"Clinical determinants, patterns and outcomes of antipsychotic medication prescribing in the treatment of schizophrenia and schizoaffective disorder: a naturalistic cohort study","volume":"158","author":"Groenendaal","year":"2023","journal-title":"J Psychiatr Res"},{"key":"2025111409271132000_ref9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/1574884715666200309121932","article-title":"Long-acting injectable vs oral antipsychotics: adherence, persistence and switching over three years of real-life analysis","volume":"16","author":"Romagnoli","year":"2021","journal-title":"Curr Clin Pharmacol"},{"key":"2025111409271132000_ref10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis","volume":"35","author":"Lin","year":"2021","journal-title":"CNS Drugs"},{"key":"2025111409271132000_ref11","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1007\/s12325-018-0786-x","article-title":"Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics","volume":"35","author":"Shah","year":"2018","journal-title":"Adv Ther"},{"key":"2025111409271132000_ref12","doi-asserted-by":"publisher","first-page":"e2224163","DOI":"10.1001\/jamanetworkopen.2022.24163","article-title":"Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia","volume":"5","author":"Wei","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025111409271132000_ref13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/1471-244x-13-221","article-title":"Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis","volume":"13","author":"Lafeuille","year":"2013","journal-title":"BMC Psychiatry"},{"key":"2025111409271132000_ref14","first-page":"18","article-title":"Treatment adherence and insight in schizophrenia","volume":"30","author":"Bitter","year":"2015","journal-title":"Psychiatr Hung"},{"key":"2025111409271132000_ref15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4088\/JCP.08m04221","article-title":"Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"J Clin Psychiatry."},{"key":"2025111409271132000_ref16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2005.09.002","article-title":"Factor structure and external validity of the PANSS revisited","volume":"82","author":"Van den Oord","year":"2006","journal-title":"Schizophr Res"},{"key":"2025111409271132000_ref17","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: DSM-5","author":"American Psychiatric Association","year":"2013"},{"key":"2025111409271132000_ref18","first-page":"217","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"2025111409271132000_ref19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/0019-5545.102419","article-title":"Factor analysis of positive and negative syndrome scale in schizophrenia: an exploratory study","volume":"54","author":"Kumar","year":"2012","journal-title":"Indian J Psychiatry"},{"key":"2025111409271132000_ref20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4088\/jcp.08l04528","article-title":"Aripiprazole-induced agitation after clozapine discontinuation: a case report","volume":"70","author":"Cho","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"2025111409271132000_ref21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4088\/jcp.v65n0122b","article-title":"Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?","volume":"65","author":"DeQuardo","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"2025111409271132000_ref22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1592\/phco.27.9.1339","article-title":"Agitation associated with aripiprazole initiation","volume":"27","author":"Lea","year":"2007","journal-title":"Pharmacotherapy."},{"key":"2025111409271132000_ref23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","article-title":"Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies","volume":"72","author":"Furukawa","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2025111409271132000_ref24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40263-020-00745-1","article-title":"Pharmacokinetics, sa,fety, and tolerability of a 2-month dose interval regimen of the long-acting injectable antipsychotic aripiprazole lauroxil: results from a 44-week phase I study","volume":"34","author":"Weiden","year":"2020","journal-title":"CNS Drugs"},{"key":"2025111409271132000_ref25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","article-title":"Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia","volume":"55","author":"Weiden","year":"2004","journal-title":"Psychiatr Serv"},{"key":"2025111409271132000_ref26","doi-asserted-by":"crossref","first-page":"22m14544","DOI":"10.4088\/JCP.22m14544","article-title":"Treatment journey from diagnosis to the successful implementation of a long-acting injectable antipsychotic agent in young adults with schizophrenia","volume":"84","author":"Kane","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"2025111409271132000_ref27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4172\/2155-6105.1000324","article-title":"CGI-SCH commonly used symptoms rating scales in schizophrenia and comparison to newer scales CAINS, BNSS","volume":"8","author":"Kumari","year":"2017","journal-title":"J Addict Res Ther"},{"key":"2025111409271132000_ref28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res"}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgaf023\/64710665\/sgaf023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/6\/1\/sgaf023\/64710665\/sgaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/6\/1\/sgaf023\/64710665\/sgaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:27:17Z","timestamp":1763130437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgaf023\/8286796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgaf023","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"sgaf023"}}